This test is most useful if any of these apply to you.
Urinary isocitric acid is one of the compounds reported on some organic acids panels. Researchers have studied it in relation to arterial stiffness and kidney disease, but its usefulness for preventive screening remains unproven. A result doesn't establish how efficiently your cells make energy or identify an organ that's under strain.
This is a research-stage marker. Studies have described its distribution in healthy people, but there is no validated target for improving health or evidence that adjusting treatment to this number improves outcomes.
Mitochondria are compartments inside cells that produce much of the energy your body uses. They contain the citric acid cycle, a series of chemical reactions involved in extracting energy from food. Isocitrate forms when citrate is rearranged during this cycle.
The protein isocitrate dehydrogenase helps convert isocitrate to alpha-ketoglutarate. Some forms of this protein can also run the reaction in reverse, so describing every isocitrate reaction as a one-way step is inaccurate.
The amount reaching your urine depends on metabolism and kidney handling. A urine concentration therefore doesn't directly measure how quickly the cycle is running inside a particular tissue. Comparing neighboring compounds can describe a pattern, but it can't establish where a reaction is slowing.
Quantitative urine organic acid testing uses laboratory techniques that separate and identify individual compounds. Results are commonly expressed relative to urine creatinine. This helps account for urine dilution, although creatinine also varies with muscle mass, age, and kidney function. A spot-sample ratio and the total amount excreted over 24 hours are different measurements.
In a study of 330 Korean adults attending routine checkups, higher urine isocitrate was associated with greater arterial stiffness. Researchers measured stiffness using the speed of a pressure wave traveling from the arm to the ankle. The association remained after accounting for several cardiovascular risk factors and medications.
The study measured urine and arterial stiffness at the same point in time. It couldn't establish which changed first, whether isocitrate contributed to stiffness, or whether the urine result predicted future heart attacks. Proposed explanations involving altered enzyme activity were hypotheses, not findings demonstrated in participants' blood vessels.
In a study of adults with stage 3 to 4 chronic kidney disease without diabetes, 24-hour urinary isocitrate excretion was about 41% lower than in healthy controls. Lower excretion was also found in an independent cohort. Separate kidney tissue analyses showed reduced expression of several genes involved in the citric acid cycle.
These findings support a connection with altered kidney metabolism. They don't establish low urinary isocitrate as a diagnostic test for kidney disease. The study's 24-hour excretion measurements also can't be treated as equivalent to a creatinine-adjusted spot urine result.
Studies in type 2 diabetes have linked other urinary citric acid cycle compounds to worsening kidney function. An earlier study found associations involving fumarate and malate, while people whose kidney function worsened had lower citrate. A later, larger investigation also associated higher fumarate and lower citrate with worsening kidney outcomes.
Those studies didn't measure isocitrate. Their findings don't establish that higher urine isocitrate predicts diabetic kidney disease, or that all compounds in this cycle move in the same direction.
Plasma isocitrate has been studied more directly in relation to later disease. In a Spanish study of adults at high cardiovascular risk, people in the highest quarter of plasma isocitrate had about 2.6 times the odds of developing heart failure compared with those in the lowest quarter during roughly a decade of follow-up. This was an observational association.
Another study followed 309 people for several years after an acute coronary event. Higher plasma isocitrate was associated with cardiovascular events and death, but the associations were no longer statistically significant after accounting for kidney filtration. The cardiovascular-event association also didn't survive correction for the number of comparisons tested.
Plasma studies have also reported associations with future type 2 diabetes and fatty liver disease. The baseline diabetes association didn't remain statistically significant after correction for multiple comparisons. The small fatty liver study found higher plasma isocitrate in affected participants but didn't establish that it could distinguish simple fat accumulation from liver inflammation.
Blood and urine results reflect different aspects of metabolism and kidney handling. These plasma findings don't validate urinary isocitrate for predicting heart failure, diabetes, or liver disease.
Repeated measurements can show whether a finding persists under similar conditions. They don't establish whether the change represents better energy production or lower disease risk. Isocitrate-specific thresholds for a clinically meaningful change haven't been established, and variation estimates from urine albumin, amino acids, or kidney stone testing can't supply them.
The opposing associations reported in arterial stiffness and established kidney disease are another reason to avoid treating either direction as universally desirable. A trend needs context from your health history and established measures of the condition you're evaluating.
Evidence-backed interventions that affect your Isocitric Acid level
Isocitric Acid is best interpreted alongside these tests.
Isocitric Acid is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers